Abbott Deals for Drug Candidate – Analyst Blog
Source: http://www.zacks.com/stock/news/27556/Abbott+Deals+for+Drug+Candidate+-+Analyst+BlogPosted on Monday, November 23rd, 2009 | In Investing Lessons, Stocks to Watch
Abbott Labs (ABT) recently signed a definitive agreement with PanGenetics BV for a pain candidate, PG110. Under the terms of the agreement, Abbott will acquire global rights to PG110 which is a novel biologic that targets Nerve Growth Factor (NGF) for the treatment of chronic pain.
PanGenetics will receive an upfront payment of $170 million and $20 million in milestone payments. This agreement should allow Abbott to expand its pain product portfolio and leverage its expertise in biologics. The commercial opportunity in the pain market is significant. There is major demand for the development of a treatment that would provide relief from pain without the potential of addiction and abuse.
It is estimated that there are about 72 million diagnosed chronic pain patients in the U.S. and EU, and up to 30% of chronic pain patients get inadequate relief. Current treatments include non-steroidal anti-inflammatory drugs (NSAIDs), certain Cox-II inhibitors, opioids and other drugs that may have various tolerability and safety issues, including the potential for abuse and addiction.
PG110 is currently in a phase I study in patients with osteoarthritis. The successful completion of this study would allow Abbott to explore the candidate’s potential in other pain indications like chronic lower back pain, cancer pain and diabetic neuropathic pain.
The deal is scheduled to close by year end. Abbott maintained its previously announced guidance for 2009.
We currently have a Neutral rating on Abbott. While economic weakness has slowed sales of a number of products in 2009, Abbott is weathering the storm relatively well. Abbott’s strong business segments, contributions from recent acquisitions and impressive late-stage pipeline should help fortify long-term earnings growth.
Read the full analyst report on “ABT”
Zacks Investment Research
Last 5 posts by Zacks Market Commentaries
- Switched Digital Video Thriving - Analyst Blog - February 9th, 2010
- Boeing Progressing on 747-8 - Analyst Blog - February 9th, 2010
- Atmel Beats Expectations - Analyst Blog - February 9th, 2010
- Aeropostale Lifts Guidance - Analyst Blog - February 9th, 2010
- Label Expansion for AZN Drug - Analyst Blog - February 9th, 2010
 About Zacks Market Commentaries (http://www.zacks.com/)
Zacks Market Commentaries |
No recommendations, either expressed or implied, are being made to buy, sell, hold or short any of the mentioned stocks. No legal, tax or accounting advice is expressed or implied. Always contact your attorney, CPA, or tax advisor before acting on any legal or tax issues. StraightStocks.com is not responsible for the content, products, or services of any of the advertisers on this site. StraightStocks.com receives compensation from advertisers on this blog. Services and products referred to herein are trademarks, registered trademarks, servicemarks, and/or registered servicemarks of their respective trademark or servicemark owners.
November 24th, 2009 at 4:17 pm
chronic pain narcotic opioids are effective but very dangerous, should be taken with moderation and prescribed by a doctor, medicines like hydrocodone, lortab, vicodin, norco, percocet, oxycontin, are even more commercial and very helpful to people with diseases such as fibromyalgia, chronic pain, Parkinson’s, arthritis, should be restricted and controlled as in findrxonline said that the FDA does not permit free marketing for them.